Lenalidomide and Azacitidine for Adaptive Immunotherapy in Multiple Myeloma: Pilot Study of Autologous Lymphocyte Mobilization Following Immuno-modulatory Therapy
Latest Information Update: 08 Nov 2021
Price :
$35 *
At a glance
- Drugs Azacitidine (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 18 Oct 2016 Status changed from active, no longer recruiting to completed.
- 02 Oct 2015 Endpoints modified as reported in the protocol amendment reported by ClinicalTrials.gov.
- 02 Oct 2015 Planned End Date changed from 1 Jan 2017 to 1 Aug 2017, according to ClinicalTrials.gov record.